The Cell and Gene Therapy (CGT) market is rapidly evolving from niche, cutting-edge science to FDA approved therapies that can address previously un-treatable diseases. With a rich pipeline of CGTs at various stages of development, yet continued manufacturing, regulatory, and access challenges, the crucial question to translating these incredible medical advances to approved and available products is “How can CGTs revolutionize the commercialization model to successfully bring life-changing therapies to patients sooner?”
With deep experience supporting CGT companies across the value chain, Trinity Life Sciences brings deep strategic expertise and analytical capabilities to address commercialization questions and challenges. Over the last few years, our extensive, global commercialization expertise and deep disease area experience has enabled us to support the launches of some of the most impactful cell and gene therapies. We continue to help our clients navigate unique commercialization challenges faced by this class of specialized treatments.
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More
Webinars
Annual State of Global Market Access Webinar
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]
Watch Now
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More
Executive Director &
Head of Cell & Gene Therapy
Partner,
Strategic Advisory
Partner &
Head of Launch Excellence
Senior Partner &
Head of Advisory
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.
